You can buy or sell MannKind and other stocks, options, ETFs, and crypto commission-free!
MannKind Corporation Common Stock, also called MannKind, is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. Read More The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
Westlake Village, California
52 Week High
52 Week Low
Seeking AlphaMar 23
MannKind - Afrezza Scripts Still Flat Despite Advertising
When the new year arrived, MannKind (MNKD) investors had an air of excitement. The company was flush with $70 million in cash and had announced that it would initiate its largest television advertising campaign and launch a direct to consumer purchase program which would give great pricing on Afrezza to the first 1,000 patients. The advertising started with a bang, logging two consecutive weeks where ad spots topped 300 airings. Since then the campaign has become a bit more modest. The Direct to Consumer p...
Seeking AlphaMar 19
MannKind May Need To Sell Its Only FDA Approved Medication Afrezza To Advance Its Pipeline
To ensure access to Afrezza for adults and children in the future, it may be in MannKind's best interests to sell Afrezza to a committed partner.
Seeking AlphaMar 16
MannKind - Scripts, Sponsorships, Warrants
MannKind (MNKD) investors are quite a happy bunch over the past week or so. The stock has marched above $2.00 per share, and the company seems to have been able to put a bit of news on the table with an Associate Sponsorship of an Indy car participating in the Indianapolis 500. It also appears that the previously undisclosed compound in a deal with United Therapeutics (NASDAQ:UTHR) has been unearthed. Before getting into scripts, let's cover the other news. The undisclosed compound appears to be Adcirca, c...
Expected May 9, Pre-Market